BioSpace News Archive

Virtūs Nutrition plans to expand their e-commerce availability following a successful appearance at May’s ECRM conference.

BioCardia®, Inc. , (OTC: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. New consents have also taken place at additional centers.

Completes recruitment of patients with first line Non-Small Cell Lung Cancer (NSCLC) 81 patients out of up to 109 now participating across the trial, with recruitment continuing for Part B and stage 2 of Part C Further interim data from TACTI-002 expected throughout CY20 SYDNEY, Australia, June 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune di

KBP-5074 is a highly-selective non-steroidal mineralocorticoid receptor antagonist with potentially reduced hyperkalemia risk Article published online; to be included in July 2020 print edition of Hypertension PRINCETON, N.J., June 29, 2020 (GLOBE NEWSWIRE) -- KBP Biosciences, a clinical stage biotechnology company dedicated to research, development and commercialization of innovative medicines for the global market, today announced the publication of the trial design for BLOCK CKD ( Blo

Beckman Coulter today announced that its Access SARS-CoV-2 IgG assay has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA). Beckman Coulter has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S., and has begun distribution of the new antibody test globally to countries that accept the FDA EUA and CE Mark.

ImpediMed Limited, a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced a national purchasing a

Study demonstrated inhibiting phosphodiesterase-1 with ITI-214 in patients with heart failure improved cardiac function by enhancing cardiac contractility and dilating systemic arteries without inducing abnormal heart rhythms.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will be added to the Russell 2000 ® Index, as part of the 2020 Russell indexes reconstitution. The addition will be effective after the U.S. market opens on June 29, 2020 as part of th

Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, today announced the appointment of Joris Schuurmans as CEO and Dirk Pollet and Maja Sanders as Supervisory Board members. Novalis Biotech Incubation will invest in Cergent

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended by a majority of votes to re